潔美科技(002859.SZ):MLCC離型膜已經實現了向國巨、華新科、風華高科、三環集團等主要客户的穩定批量供貨
格隆匯10月26日丨潔美科技(002859.SZ)於2023年10月25日接受特定對象調研,就“公司離型膜目前進展情況?基膜切換進展情況?”,公司回覆稱,公司MLCC離型膜已經實現了向國巨、華新科、風華高科、三環集團等主要客户的穩定批量供貨,客户端中高規格產品的驗證已取得一定突破,在韓日系大客户處驗證及小批量試用也在按計劃有序推進。公司持續推進光學級BOPET膜生產項目,已在客户端全面展開使用自制基膜離型膜產品的推廣驗證,並有多規格產品通過了驗證進入小批量及逐步放量階段。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.